BridgeMD
TAR-0520 Gel in taxanes-induced peripheral neuropathy
EU CTIS ID: 2025-521674-33-00
What this study is testing
To confirm the local and systemic safety of TAR-0520 Gel applied twice daily to one hand and one foot, in breast cancer patients treated with taxanes.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female, who is at least 18 years of age or older at screening visit
- Clinical diagnosis of breast cancer planned to be treated with weekly infusions of paclitaxel or docetaxel as part of the chemotherapy protocol
You likely can't join if
- Patient already treated with taxanes or other chemotherapies known to induce neuropathies
- Patient with previously diagnosed peripheral neuropathy
- Patient with concomitant therapies known to induce neuropathies
- Patient treated for neuropathic pain
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.